122 results on '"Ogihara, Koichiro"'
Search Results
2. Role of Previous Malignancy History in Clinical Outcomes in Patients with Initially Diagnosed Non-Muscle Invasive Bladder Cancer
3. A Novel Risk-based Approach Simulating Oncological Surveillance After Radical Nephroureterectomy in Patients with Upper Tract Urothelial Carcinoma
4. Can random bladder biopsies be eliminated after bacillus Calmette–Guérin therapy against carcinoma in situ?
5. Urinary pH is an independent predictor of upper tract recurrence in non-muscle-invasive bladder cancer patients with a smoking history
6. Long-Term Oncologic Outcomes of Laparoscopic Versus Open Radical Nephroureterectomy for Patients with T3N0M0 Upper Tract Urothelial Carcinoma: A Multicenter Cohort Study with Adjustment by Propensity Score Matching
7. ASO Author Reflections: Previous History of Non-urothelial Malignancy May Provide Predictive Information of Worse Clinical Outcome for Initially Diagnosed Non-Muscle Invasive Bladder Cancer
8. The Preoperative Neutrophil-to-lymphocyte Ratio is a Novel Biomarker for Predicting Worse Clinical Outcomes in Non-muscle Invasive Bladder Cancer Patients with a Previous History of Smoking
9. Refraining from Smoking for 15 Years or More Reduced the Risk of Tumor Recurrence in Non-muscle Invasive Bladder Cancer Patients
10. Does neoadjuvant chemotherapy have therapeutic benefit for node-positive upper tract urothelial carcinoma? Results of a multi-center cohort study
11. Diagnostic performance of the vesical imaging-reporting and data system for detecting muscle-invasive bladder cancer in real clinical settings: Comparison with diagnostic cystoscopy
12. Potential therapeutic effects of adjuvant chemotherapy after neoadjuvant chemotherapy for locally advanced muscle-invasive bladder cancer
13. PREOPERATIVE NEUTROPHIL-TO-LYMPHOCYTE RATIO IS A USEFUL BIOMARKER FOR PREDICTING WORSE CLINICAL OUTCOME IN NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS WITH A PREVIOUS HISTORY OF SMOKING.: MP13-01
14. Spontaneous Regression of Epstein-Barr Virus-Positive Primary Diffuse Large Cell B-Cell Lymphoma of the Urinary Bladder After the Cessation of Enzalutamide
15. Urinary pH is An Independent Predictor of Upper Tract Recurrence in Non-Muscle-Invasive Bladder Cancer Patients with a Smoking History
16. PD17-08 REFRAINING FROM SMOKING FOR 15 YEARS OR MORE REDUCED THE RISK OF TUMOR RECURRENCE IN NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS
17. Guideline adherence for radical cystectomy significantly affects survival outcomes in non-muscle-invasive bladder cancer patients
18. Oncological outcomes of dose reductions in cisplatin due to renal dysfunction for patients with metastatic urothelial carcinoma
19. Site-specific differences in survival among upper and lower tract urothelial carcinoma patients treated with radical surgery
20. The clinicopathological characteristics of muscle‐invasive bladder recurrence in upper tract urothelial carcinoma
21. Can random bladder biopsies be eliminated after bacillus Calmette–Guérin therapy against carcinoma in situ?
22. Significance of prophylactic urethrectomy at the time of radical cystectomy for bladder cancer
23. Relationship between radiation doses and erectile function deterioration in patients with localized prostate cancer treated with permanent prostate brachytherapy
24. The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients
25. MP49-05 PRETREATMENT ABSOLUTE MONOCYTE COUNT IS A NOVEL BIOMARKER FOR PREDICTING WORSE CLINICAL OUTCOME IN CHEMO-RESISTANT UROTHELIAL CARCINOMA PATIENTS TREATED WITH PEMBROLIZUMAB
26. MP01-02 SULFASALAZINE COULD MODULATE THE CD44V9-XCT SYSTEM AND ENHANCE CDDP-INDUCED CYTOTOXIC EFFECTS IN METASTATIC BLADDER CANCER; A NOVEL THERAPEUTIC STRATEGY FOR METASTATIC BLADDER CANCER
27. MP50-15 SITE SPECIFIC DIFFERENCES IN SURVIVAL AMONG BLADDER, RENAL PELVIC, AND URETERAL UROTHELIAL CARCINOMA PATIENTS TREATED WITH RADICAL SURGERY
28. MP50-08 SIMULATING THE SURVEILLANCE DURATION OF INTRAVESICAL RECURRENCE AFTER RADICAL NEPHROURETERECTOMY: AN INDIVIDUALIZED RISK BASED APPROACH APPLYING THE WEIBULL MODEL
29. MP50-06 COULD LAPAROSCOPIC SURGERY HAVE SAME LONG-TERM ONCOLOGICAL OUTCOMES AS OPEN RADICAL NEPHROURETERECTOMY IN T3N0M0 UPPER TRACT UROTHELIAL CARCINOMA? A MULTICENTER COHORT STUDY ADJUSTED BY PROPENSITY SCORE MATCHING
30. MP63-08 CD44 VARIANT 9 EXPRESSION IS A NOVEL INDICATOR FOR IDENTIFYING POOR SURVIVAL IN PATIENTS WITH INVASIVE UROTHELIAL CARCINOMA
31. MP50-07 THE SURVIVAL PREDICTION WITH TIME OF INTRAVESICAL RECURRENCE IN UPPER TRACT UROTHELIAL CARCINOMA
32. PD66-12 A NOVEL RISK BASED APPROACH SIMULATING ONCOLOGIC SURVEILLANCE ACCORDING TO SMOKING STATUS AFTER RADICAL NEPHROURETERECTOMY WITH UPPER TRACT UROTHELIAL CARCINOMA
33. MP26-01 PRETREATMENT NEUTROPHIL-TO-LYMPHOCYTE RATIO IS A NOVEL BIOMARKER FOR PREDICTING WORSE CLINICAL OUTCOME IN CHEMO-RESISTANT UROTHELIAL CARCINOMA PATIENTS TREATED WITH PEMBROLIZUMAB
34. Sulfasalazine could modulate the CD 44v9‐ xCT system and enhance cisplatin‐induced cytotoxic effects in metastatic bladder cancer
35. Single-cell RNA-seq analysis reveals the platinum resistance gene COX7B and the surrogate marker CD63
36. Significance of prophylactic urethrectomy at the time of radical cystectomy for bladder cancer.
37. MP41-07 COULD ADJUVANT CHEMOTHERAPY HAVE ADDITIONAL THERAPEUTIC BENEFIT IN BLADDER CANCER PATIENTS TREATED WITH RADICAL CYSTECTOMY AND NEOADJUVANT CHEMOTHERAPY?
38. MP78-15 CAN UROLOGISTS INTRODUCE THE CONCEPT OF “OLIGOMETASTASIS” FOR METASTATIC BLADDER CANCER AFTER RADICAL CYSTECTOMY?
39. Preoperative sarcopenia status is associated with lymphovascular invasion in upper tract urothelial carcinoma patients treated with radical nephroureterectomy
40. Can urologists introduce the concept of “oligometastasis” for metastatic bladder cancer after total cystectomy?
41. PD48-10 PREOPERATIVE NEUTROPHIL-TO-LYMPHOCYTE RATIO AND SMOKING HISTORY ARE INDEPENDENTLY ASSOCIATED WITH BCG RELAPSING TUMOR RECURRENCE IN NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS
42. MP34-16 COULD ADJUVANT CHEMOTHERAPY HAVE THERAPEUTIC BENEFIT AFTER NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH EQUAL TO OR GREATER THAN PT3 MUSCLE INVASIVE BLADDER CANCER?
43. PD48-09 PURIFIED PROTEIN DEPRIVATION SKIN TEST REACTION IS ASSOCIATED WITH CLINICAL OUTCOME OF PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER TREATED WITH BACILLUS-CALMETTE GUERIN
44. MP15-03 WHO COULD BE ELIMINATED FOR RANDOM BIOPSIES AFTER BCG THERAPY IN PATIENTS WITH BLADDER CARCINOMA IN SITU?
45. PD17-03 'TUMOR BUDDING', A NOVEL PROGNOSTIC INDICATOR FOR PREDICTING STAGE PROGRESSION IN T1 BLADDER TUMORS
46. Sulfasalazine could modulate the CD44v9‐xCT system and enhance cisplatin‐induced cytotoxic effects in metastatic bladder cancer.
47. MP56-04 IMPACT OF LYMPHOVASCULAR INVASION STATUS IN TRANSURETHRAL RESECTION OF BLADDER TUMORS COULD PREDICT SUBSEQUENT STAGE PROGRESSION IN T1 BLADDER TUMORS
48. Tumor budding, a novel prognostic indicator for predicting stage progression in T1 bladder cancers
49. MP13-01 PREOPERATIVE NEUTROPHIL-TO-LYMPHOCYTE RATIO IS A USEFUL BIOMARKER FOR PREDICTING WORSE CLINICAL OUTCOME IN NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS WITH A PREVIOUS HISTORY OF SMOKING.
50. Refraining from Smoking for 15 Years or More Reduced the Risk of Tumor Recurrence in Non-muscle Invasive Bladder Cancer Patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.